{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:14:41Z","timestamp":1783574081898,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bone metastasis (BM) is common in newly diagnosed prostate cancer (PCa), particularly in patients with advanced disease at presentation. However, the indications for bone scintigraphy remain inconsistent and may lead to unnecessary imaging in low-risk patients. This study aimed to develop and validate a machine learning model for individualized prediction of BM in patients with newly diagnosed PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected data from 327 patients with newly diagnosed PCa from two tertiary hospitals. Patients were randomly assigned to a training set (n = 229) and an internal validation set (n = 98). The Boruta algorithm was used to identify significant predictors. Seven machine learning models, including random forest and logistic regression, were developed and evaluated using five-fold cross-validation. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration, and decision curve analysis (DCA). The best-performing model was interpreted using SHapley Additive exPlanations (SHAP) and deployed as an online prediction tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six predictors were identified by the Boruta algorithm: clinical T stage, Gleason score, total prostate-specific antigen (tPSA), alkaline phosphatase (ALP), regional lymph node metastasis, and fibrinogen. Among the seven models, the random forest model achieved the best performance, with an area under the curve (AUC) of 0.902 in the training set and 0.906 in the internal validation set. Calibration curves showed good agreement between predicted and observed outcomes, and decision curve analysis indicated favorable clinical utility. An interactive online prediction tool was developed for individualized risk estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We developed and internally validated an interpretable random forest model for predicting BM in newly diagnosed PCa. This model may help identify high-risk patients and guide the use of bone scintigraphy. Prospective multicenter studies with external validation are needed to further confirm its generalizability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1815465","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:20:02Z","timestamp":1783570802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a machine learning-based early warning model for bone metastasis in newly diagnosed prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Leibo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Surgery, Beijing Jishuitan Hospital Guizhou Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Surgery, Beijing Jishuitan Hospital Guizhou Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"lv","sequence":"additional","affiliation":[{"name":"Surgery, Beijing Jishuitan Hospital Guizhou Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpo","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Jishuitan Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyi","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wen","sequence":"additional","affiliation":[{"name":"Shenzhen Nanshan Medical Group Headquarter","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.27537","article-title":"Establishing a prediction model for prostate cancer bone metastasis","volume":"15","author":"Chen","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12894-017-0229-z","article-title":"When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/genes10020087","article-title":"Machine learning and integrative analysis of biomedical big data","volume":"10","author":"Mirza","year":"2019","journal-title":"Genes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S330591","article-title":"Application of machine learning techniques to predict bone metastasis in patients with prostate cancer","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1133","article-title":"Establishment and validation of a novel predictive model to quantify the risk of bone metastasis in patients with prostate cancer","volume":"10","author":"Lu","year":"2021","journal-title":"Transl Androl Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1133","article-title":"Establishment and validation of a novel predictive model to quantify the risk of bone metastasis in patients with prostate cancer","volume":"10","author":"Lu","year":"2021","journal-title":"Transl Androl Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202206_28950","article-title":"Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients","volume":"26","author":"Peng","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02872-x","article-title":"Management of patients with high-risk and advanced prostate cancer in the middle east: resource-stratified consensus recommendations","volume":"38","author":"Mukherji","year":"2020","journal-title":"World J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)38325-8","article-title":"Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters","volume":"145","author":"Chybowski","year":"1991","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_189_18","article-title":"Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer","volume":"15","author":"Singh","year":"2019","journal-title":"J\u00a0Cancer Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.02.010","article-title":"Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen","volume":"18","author":"Kataoka","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/qims-21-365","article-title":"Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer","volume":"12","author":"Hong","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.11.049","article-title":"Implications of serum bone turnover markers in prostate cancer patients with bone metastasis","volume":"75","author":"Kamiya","year":"2010","journal-title":"Urology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.remn.2013.01.002","article-title":"Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-na\u00efve patients with prostate cancer","volume":"32","author":"Moslehi","year":"2013","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15027707","article-title":"Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases","volume":"15","author":"Wei","year":"2016","journal-title":"Genet Mol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S168579","article-title":"The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04816-w","article-title":"Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.187286","article-title":"The factors that affect the prediction of lymph node metastasis in prostate cancer","volume":"14","author":"Turk","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211058364","article-title":"A new nomogram for the prediction of bone metastasis in patients with prostate cancer","volume":"49","author":"Bai","year":"2021","journal-title":"J Int Med Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2016.17.3.1187","article-title":"Predictors of positive bone metastasis in newly diagnosed prostate cancer patients","volume":"17","author":"Chien","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/79184355","article-title":"Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients","volume":"85","author":"McArthur","year":"2012","journal-title":"Br J Radiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer","volume":"41","author":"Falanga","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.06.010","article-title":"Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma","volume":"20","author":"Chung","year":"2020","journal-title":"Pancreatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8899994","article-title":"Systemic coagulation markers especially fibrinogen are closely associated with the aggressiveness of prostate cancer in patients who underwent transrectal ultrasound-guided prostate biopsy","volume":"2021","author":"Wang","year":"2021","journal-title":"Dis Markers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s40001-023-01562-0","article-title":"The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer","volume":"28","author":"Yu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268275","article-title":"Prospective head-to-head comparison of 18F-PSMA PET\/CT and 18F-NaF PET\/CT for assessing bone metastases in 160 patients with newly diagnosed high-risk prostate cancer","volume":"66","author":"Madsen","year":"2025","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2025.09.004","article-title":"Comparison of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities in the detection of biochemical recurrence of prostate cancer and assessment of the role of artificial intelligence: a systematic review and meta-analysis","volume":"32","author":"Zhang","year":"2025","journal-title":"Acad Radiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.7150\/ijbs.27537","article-title":"Establishing a prediction model for prostate cancer bone metastasis","volume":"15","author":"Chen","year":"2019","journal-title":"International Journal of Biological Sciences"},{"key":"B32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.urology.2024.05.027","article-title":"Development and validation of a machine learning model for bone metastasis in prostate cancer: based on inflammatory and nutritional indicators","volume":"190","author":"Jin","year":"2024","journal-title":"Urology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mri.2023.12.009","article-title":"A machine learning radiomics model based\u00a0on\u00a0bpMRI to predict bone metastasis in newly diagnosed prostate cancer\u00a0patients","volume":"107","author":"Song","year":"2024","journal-title":"Magn Reson Imaging"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.09.004","article-title":"Opening the black box: the promise and limitations of explainable machine learning in cardiology","volume":"38","author":"Petch","year":"2022","journal-title":"Can J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1127637","article-title":"The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-025-02855-5","article-title":"Exosome-transmitted long noncoding RNA SNHG1 promotes prostate cancer bone metastasis via YBX1\/MMP16 axis","volume":"12","author":"Yang","year":"2026","journal-title":"Cell Death Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24825","article-title":"Clinicopathological significance of extranodal adipose tissue invasion in metastatic lymph nodes in patients with prostate cancer","volume":"85","author":"Nagasaka","year":"2025","journal-title":"Prostate"},{"key":"B38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12935-026-04317-z","article-title":"Insulin-like growth factor-binding protein 5 promotes\u00a0prostate cancer metastasis and osteoblastic activity by inducing chemokines and activating NF-\u03baB signaling","volume":"26","author":"Gong","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0294","article-title":"Bone metastasis in endocrine-related cancer: unravelling invasion and destruction","volume":"32","author":"Duong","year":"2025","journal-title":"Endocr Relat Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1815465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:20:03Z","timestamp":1783570803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1815465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1815465"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1815465","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1815465"}}